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Background: Chemotherapy-induced peripheral neuropathy is commonly observed in patients treated
with nanoparticle albuminebound paclitaxel (nab-PTX). We conducted a multicenter randomized
controlled study to evaluate the optimal dose of nab-PTX.
Methods: We compared three different doses of q3w nab-PTX (Standard: 260 mg/m2 [SD260] vs Me-
dium: 220 mg/m2 [MD220] vs Low: 180 mg/m2 [LD180]) in patients with HER2-negative metastatic
breast cancer (MBC). Primary endpoint was progression-free survival (PFS). Grade 3/4 neuropathy rates
in the three doses were estimated using the logistic regression model. The optimal dose was selected in
two steps. Initially, if the hazard ratio (HR) for PFS was <0.75 or >1.33, the inferior dose was excluded,
and we proceeded with the non-inferior dose. Then, if the estimated incidence rate of grade 3/4
neurotoxicity exceeded 10%, that dose was also excluded.
Results: One hundred forty-one patients were randomly assigned to SD260 (n ¼ 47), MD220 (n ¼ 46),
and LD180 (n ¼ 48) groups, and their median PFS was 6.66, 7.34, and 6.82 months, respectively. The HRs
were 0.73 (95% confidence interval [CI]: 0.42e1.28) in MD220 vs SD260, 0.77 (95% CI 0.47e1.28) in LD180
vs SD260, and 0.96 (95% CI 0.56e1.66) in LD180 vs MD220. SD260 was inferior to MD220 and was
excluded. The estimated incidence rate of grade 3/4 neurotoxicity was 29.5% in SD260, 14.0% in MD220,
and 5.9% in LD180. The final selected dose was LD180.otherapy-induced peripheral neuropathy; CR, complete remission; DCR, disease control rate; DFI, disease-free interval;
nce; HR, hazard ratio; MBC, metastatic breast cancer; Nab-PTX, nanoparticle albuminebound paclitaxel; ORR, overall
ee survival; PR, partial response; PROs/HRQoL, patient-reported outcomes/health-related quality-of-life; QoL, quality-
valuation criteria in solid tumors; sb-PTX, comparing solvent-based paclitaxel; TNBC, triple-negative breast cancer; TTF,
rutani).
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J. Tsurutani, F. Hara, M. Kitada et al. The Breast 55 (2021) 63e68Conclusions: Intravenous administration of low-dose nab-PTX at 180 mg/m2 q3w may be the optimal
therapy with meaningful efficacy and favorable toxicity in patients with MBC.
© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The primary goal of patient care in metastatic breast cancer
(MBC) is palliation and maintaining good quality-of-life (QoL)
throughout the disease course, along with prolonging survival.
Chemotherapy remains the mainstay of patient care, and choosing
an appropriate drug and optimizing the required dose are keys to
achieving this goal.
Nab-paclitaxel (nab-PTX) is an albumin-stabilized nanoparticle
formulation of paclitaxel and can be administered without ethanol
or steroid premedication [1]. Currently, nab-PTX is approved for
treating breast, gastric, lung, and pancreatic cancers, and intrave-
nous administration at 260 mg/m2 every 3 weeks (q3w) is the only
indication for treating breast cancer with nab-PTX in Japan, US, and
EU.
A Phase III study, CA012, comparing solvent-based paclitaxel
(sb-PTX) (175 mg/m2, q3w) with nab-PTX (260 mg/m2, q3w) was
conducted in patients with MBC [2]. The overall response rates
(ORR) and progression-free survival (PFS) were significantly supe-
rior in the nab-PTX arm than in the sb-PTX arm. However,
chemotherapy-induced peripheral neuropathy (CIPN) at grade 3 or
higher occurredmore frequently in the nab-PTX arm than in the sb-
PTX arm (10.5% vs 2.2%, respectively).
Another Phase III trial, CALGB 40502, compared three regimens:
weekly sb-PTX (90 mg/m2), weekly nab-PTX at 150 mg/m2, and
ixabepilone (16 mg/m2) with bevacizumab (10 mg/kg) every 2
weeks as first-line chemotherapy for MBC [3]. Compared with sb-
PTX, nab-PTX did not improve PFS in the study, and CIPN was
significantly higher in the nab-PTX arm than in the sb-PTX arm
(25% vs 16%).
According to the post-marketing surveillance of nab-PTX use in
Japanese breast cancer patients, one-third of patients required dose
reductions after receiving an initial dose [4]. Although the recom-
mended dosage of nab-paclitaxel by the Pharmaceuticals and
Medical Devices Agency, the US Food and Drug Administration, and
European Medicines Agency is 260 mg/m2 intravenously over
30 min every 3 weeks, for MBC, 27.3% of patients starting at this
dose required subsequent reductions. Grade 2/3 CIPN was
frequently observed (42.5% and 10.8%, respectively). Therefore,
further studies are required to find the optimal dose of q3w nab-
PTX in Japanese patients.
Nab-PTX promptly collapses in the blood to yield albumin-
bound PTX and is efficiently delivered to tumor cells [5]. Nab-PTX
is more efficient than sb-PTX even at similar doses. Several
studies have demonstrated the safety and efficacy of nab-PTX q3w
at reduced doses [6e8]. In a single arm Phase II trial, CA002-0LD,
nab-PTX was administered at 175 mg/m2 q3w. The resulting ORR
was 39.5% and no grade 3/4 CIPN was observed [6]. Thus, the
effectiveness of lower-dose nab-PTX may be similar to that of
standard-dose nab-PTX. Here, we conducted a randomized Phase II
study to optimize the nab-PTX dose comparing three different
doses of nab-PTX (180 mg/m2 vs 220 mg/m2 vs 260 mg/m2) q3w, in
patients with MBC.642. Materials and methods
2.1. Patients
Patients between 20 and 75 years of age with pathologically
confirmed stage IV breast adenocarcinoma, an Eastern Cooperative
Oncology Group performance status (ECOG) of 0 or 1, and up to one
chemotherapy regimen for MBC were eligible for the study. If
sensory neuropathy was present, it was restricted to grade 1 for
inclusion. Neoadjuvant or adjuvant chemotherapy followed by one
line of chemotherapy for MBCwas allowed if 6 or moremonths had
elapsed from the end of neo- or adjuvant chemotherapy to the
diagnosis of recurrence. Patients were excluded if they were
receiving concurrent immunotherapy or hormonal therapy for
breast cancer or had parenchymal brain metastases (unless stable),
a history of class II to IV congestive heart failure, or other malig-
nancy within the last 5 years that could affect the diagnosis or
assessment of breast cancer.
2.2. Study design
The study was approved by an appropriate institutional review
board and all patients provided informed consent for participation.
The CSPOR Data Centre confirmed patient eligibility, and treatment
was assigned using a minimization method with the allocation
factors for eligible patients. The allocation factors were as follows:
institution, hormone sensitivity, prior chemotherapy, taxane, and
disease-free interval (DFI) from surgery.
2.3. Study end points
The primary endpoint was PFS, which was defined as the time
from the date of randomization to that of disease progression or
death, whichever occurred first. Secondary endpoints included
time-to-treatment failure (TTF), overall survival (OS), ORR, disease
control rate (DCR), adverse events, and patient-reported outcomes/
health-related quality-of-life (PROs/HRQoL). QoL was assessed in
this trial and the results has been submitted separately to another
journal.
2.4. Tumor assessments
Tumor responses were assessed every 6 weeks for the first 18
weeks and every 9 weeks thereafter (regardless of treatment
schedule). Patients with measurable disease were evaluated for
complete remission (CR), partial response (PR), stable disease, or
progressive disease per the Response evaluation criteria in solid
tumors (RECIST) guidelines.
For safety or tolerability evaluations, investigator-assessed
incidence of adverse events was reported. Laboratory abnormal-
ities and incidence of dose modifications or interruptions, with
premature discontinuation of the study drug, were recorded. All
toxicities were graded according to the National Cancer Institute
J. Tsurutani, F. Hara, M. Kitada et al. The Breast 55 (2021) 63e68Common Terminology Criteria for Adverse Events (version 4.0).
2.5. Statistical methods
The purpose of the main analysis was to select the optimal dose
that conferred reasonable PFS and tolerable neurotoxicity profile,
from the three tested dose levels [9]. We defined the optimal dose
as that where the PFS was not inferior to PFS of SD260, and where
the grade 3 neurotoxicity rate was less than 10%. The selection
consisted of two steps. First, pairwise comparison of PFS was con-
ducted using three Cox regressions, each of which included two
dose groups of the three tested doses. If the HR was outside the
range of 0.75 and 1.33, the inferior dose groupwas excluded andwe
proceeded with the non-inferior doses. Second, we chose the
greatest dose level from the dose groups whose estimated inci-
dence probability of grade 3/4 neurotoxicity was less than 10%. The
neurotoxicity probabilities in the three dose groups were estimated
by the single logistic regression including the doses as a continuous
variable, because the dose-dependent increase in neurotoxicity was
regarded as a reasonable assumption. Regardless of the result of the
first dose-selection step, the logistic regression included all dose
groups to precisely estimate the dose-toxicity curve. If the esti-
mated neurotoxicity incidence exceeded 10% at any non-inferior
dose levels, we chose the lowest dose level. This design, called
the selection design [9], selects the optimal dose worthy of further
investigation in a subsequent phase III trial based on the HR esti-
mates of the PFS and the estimates of neurotoxicity incidenceFig. 1. Consort diagram. One hundred forty-one patients were enrolled in the study
and randomized into one of three groups: SD260 or MD220 or LD180, where the
subjects were treated with 260 mg/m2 or 220 mg/m2 or 180 mg/m2 of nab-PTX,
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65probability of the three arms; not based on their confidence in-
tervals. In this respect, this selection design is different from the
ordinary non-inferiority and superiority trials, and the definition of
non-inferiority on PFS is also different as described above.
According to the selection design, the required sample size was
calculated based on the probability that the true optimal dose is
correctly chosen by the above two-step procedure. The study was
planned to ensure the selection of an MD220 with a probability of
70%, when the one-year PFSs of all three doses were 30% and the
grade 3 neurotoxicity rates of SD260, MD220, and LD180 were 15%,
8%, and 0.1%, respectively. This required 40 patients per group with
expected registration periods of two years and follow-up periods of
two years. Eventually, we chose 42 patients per group. Other sim-
ulations are provided in the Supplementary Table S1.
The protocol was registered at the website of the University
Hospital Medical Information Network (UMIN), Japan (protocol ID
UMIN000012429), on November 1, 2014. The details are available at
the following web address: http://www.umin.ac.jp/ctr/.3. Results
3.1. Enrolment
Between February 2015 and February 2017, 141 patients were
enrolled and randomly assigned to different dose groups. One pa-
tient did not start treatment in the MD220 arm (Fig. 1). Overall, 47
patients were treatedwith SD260 of nab-PTX; 46, withMD220; and
48, with LD180. At the time of reporting, all patients had stopped
the study therapy. The median follow-up time was 25 months.
Patient characteristics were well-balanced between the study
arms except with performance status 1a, which was a little higher
in LD (Table 1). Median age was 57 years. Seventy-four percent of
patients had visceral metastases and an ECOG of zero; 78% had
hormone receptor-positive disease; and 22% triple-negative BC
(TNBC) tumors. Among treated patients, 55% had a DFI from the
diagnosis of primary tumor to diagnosis of metastatic disease of
more than 2 years, 26% received chemotherapy for MBC, and 38%
received prior taxanes.3.2. Dose selection
Median PFS was 6.66 (95% CI 4.82e8.82), 7.34 (95% CI
4.59e8.92), and 6.82 months (95% CI 4.43e9.15) in the SD260,
MD220, and LD180 groups, respectively (Fig. 2). The HRs were 0.73MD220 LD180 P-value
(n ¼ 45) (n ¼ 48)
61.0 (34e74) 58.5 (35e74) 0.82
0.22
34 (75.6%) 31 (64.6%)
10 (22.2%) 17 (35.4%)
34 (75.6%) 37 (77.1%) 0.88
22 (48.9%) 27 (56.3%) 0.53
0.93
12 (26.7%) 11 (22.9%)
24 (53.3%) 27 (56.3%)
9 (20.0%) 10 (20.8%)
0.96
11 (24.4%) 13 (27.1%)
34 (75.6%) 35 (72.9%)
0.88
17 (37.8%) 17 (35.4%)
28 (62.2%) 31 (64.6%)
Fig. 2. Progression-free survival by treatment groups. Curves were drawn using
Kaplan-Meier estimation by the assigned groups. Events were defined as disease
progression or death by any causes.
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(95% CI 0.47e1.28) in LD180 vs SD260, and 0.96 (95% CI 0.56e1.66)
in LD180 vs MD220. SD260 was inferior to MD220 and was
excluded (Table 2). In the second stage, the frequencies estimated
by logistic regression for CIPN G3/4 were 14.0% and 5.9% for MD220
and LD180, respectively (Table 2), and MD220 exceeding 10% were
excluded. Resultantly, LD180was selected as themost optimal dose.
3.3. Efficacy
ORRs were 48.7%, 44.1%, and 37.8% in SD260, MD220, and LD180,
respectively. The OS events occurred at 77/140 (55%) at the time of
analysis, and the median OS was 2.1, 2.8, and 2.5 years for SD260,
MD220, and LD180, respectively There were no significant differ-
ences between treatment groups. The TTFs were similar betweenTable 2
Selection of the optimal dose.
Cox regression Hazard ratio (HR) of PFS
Estimate 95% CI
MD220 vs SD260 0.73 (0.42, 1.28)
LD180 vs SD260 0.77 (0.47, 1.28)
LD180 vs MD220 0.96 (0.56, 1.66)
Logistic regression Incidence (%) of CIPN ¼ /> Gr3
Estimate 95% CI
SD260 29.5 (18.7, 43.2)
MD220 14 (8.8, 21.6)
LD180 5.9 (2.3, 14.6)
CI, confidence interval.
a If HR<0.75 or >1.33, the inferior one was excluded.
b The dose with its estimated incidence rate exceeding 10% was excluded.
Table 3
Adverse events.
Events SD260: n, (%) M
Any Grade3 A
No. of patients n ¼ 47 n
Leukopenia 31 (66.0) 9 (19.1) 3
Neutropenia 27 (57.4) 12 (25.4) 3
Hemoglobin 27 (57.4) 1 (2.1) 2
ALT elevation 26 (55.3) 1 (2.1) 2
Fatigue 38 (80.9) 1 (2.1) 3
Sensory neuropathy 43 (91.5) 15 (31.9) 3
Arthralgia 35 (74.5) 4 (8.5) 3
Myalgia 34 (72.3) 6 (12.8) 2
Rash 16 (34.1) 0 (0.0) 1
Anorexia 24 (51.1) 1 (2.1) 2
66these groups (5.31, 5.11, and 5.28 months, respectively).
3.4. Toxicity
The common adverse events were sensory neuropathy, fatigue,
arthralgia, myalgia, and leukopenia (Table 3). Grade3/4 sensory
neuropathy andmyalgiaweremore commonly observed in patients
who received SD260 and MD220 than in those who received LD180
(Table 3: 31.9, 8.9 vs 8.3% and 12.8, 6.7 vs 0%, respectively,
Supplementary Figure S1). Notably, sensory neuropathy of grade 2
or higher was more common, and rapidly occurred in the SD260
group than in the MD220 or LD180 groups (Fig. 3).
Grade 3/4 neutropenia events were more common in SD260 or
MD220 than in LD180 groups (Table 3: 25.4, 37.7 vs 14.7%,
respectively). The dose reduction rate during treatment was
significantly higher in SD260 group than in the other groups
(Table 4).
3.5. Relative dose intensity (RDI)
The RDI in each group to the planned SD260 regimenwere 0.87,
0.77, and 0.63 in SD260, MD220, and LD180, respectively (Table 5).
4. Discussion
This is the first randomized control study that has compared the
reduced doses of nab-PTX with the standard dose (260 mg/m2)
q3w, in patients with MBC, and evaluated the non-inferiority (with
the intention of selecting the optimal dose) of the reduced initial
doses to the standard dose, in terms of PFS and the adverse events,
including CIPN. We found that LD180 was not inferior to SD260 or
MD220 and selected this dose because it had less than 10% of theSelectiona




Not candidate for 2nd selection
Drop MD220 due to estimated incidence rate exceeding 10%
Retain LD180
D220: n, (%) LD180: n, (%)
ny Grade3 Any Grade3
¼ 45 n ¼ 48
5 (77.8) 12 (26.6) 29 (60.4) 7 (14.6)
3 (73.3) 17 (37.7) 24 (50.0) 7 (14.6)
2 (48.9) 1 (2.2) 28 (58.3) 2 (4.2)
0 (44.4) 2 (4.4) 18 (37.5) 0 (0.0)
5 (77.8) 0 (0.0) 34 (70.8) 0 (0.0)
8 (84.4) 4 (8.9) 39 (81.3) 4 (8.3)
0 (66.7) 5 (11.1) 27 (56.3) 0 (0.0)
6 (57.8) 3 (6.7) 19 (39.6) 0 (0.0)
4 (31.1) 0 (0.0) 12 (25.0) 0 (0.0)
3 (51.1) 0 (0.0) 20 (41.7) 1 (2.1)
Fig. 3. Accumulated incidences of G2/3/4 neuropathy are shown by the treatment
groups.
Table 5
Relative dose intensity (RDI).
n RDI 95% CI
LD180 48 0.63 0.61 0.65
MD220 45 0.77 0.75 0.8
SD260 46 0.87 0.84 0.91
CI, confidence interval.
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Gradishar and colleagues have reported that the administration
of nab-PTX at 260 mg/m2 q3w improved clinical outcomes, such as
ORR and PFS, and had a more favorable safety profile, when
compared to administration of sb-PTX at 175 mg/m2, in previously
untreated patients with MBC [2]. Nonetheless, compared to the
results of the pivotal study [2], the incidence of grade 3/4 neu-
ropathy was higher in the group with the SD260 (10.4 vs 31.9%,
respectively), and the grade 3/4 myalgia was not trivial in the
current study (12.8%) unlike in the pivotal study. The cause of this
inconsistency between the studies, in terms of the incidence of
CIPN and myalgia is not clear, but may be attributed it to the dif-
ferences in ethnicity between the subjects enrolled in both studies.
Another study reported that the incidence and degree of CIPN were
extremely high and severe, respectively, among Japanese patients
with the SD regimen (84% grade 3/4) [10]. The common and severe
CIPN and myalgia requiring interruption or reduction of the dose
would rationalize further modification of the SD260 regimen in
Japanese patients to ensure a good QoL.
To this end, multiple studies, including the current one, have
evaluated the lower dose of nab-PTX, q3w to establish modified
doses that can alleviate the CIPN and myalgia [6e8]. These have
reported that the regimen of 180 mg/m2 of nab-PTX achieved
23e41% of ORRs and 23e26 weeks of PFS with 0e6% of grade3/4
CINP. Their results are consistent with those of the current study,
with regard to the efficacy and toxicity of the LD180 regimen
compared to the SD260 treatment, highlighting the increased
tolerability of this treatment without compromising the efficacy.Table 4
Dose reductions.
Treatment Arm
SD260 (n ¼ 47) MD220
Dose reduction n % 95% CI n
Yes 19 40.4 (26.4, 55.7) 11
No. of dose reduction
1 14 29.8 (17.3, 44.9) 8
2 5 10.6 (3.5, 23.1) 3
By treatment course
By 1st course 0 0 (0, 7.5) 0
By 2nd course 3 6.4 (1.3, 17.5) 1
By 3rd course 5 8.5 (2.4, 20.4) 2
CI, confidence interval.
67Notably, the current study is the only one to randomize patients
according to standard or low-dose regimens, to clarify the differ-
ences in therapeutic indices of the variable doses [6e8]. Interest-
ingly, all three of these studies showed uncompromising PFS with
the LD180 regimen, implying that the dose-PFS relationship, but
not the dose-toxicity one, had plateaued at 180 mg/m2 of nab-PTX
q3w, and the therapeutic index of nab-PTX was higher than that of
sb-PTX, due to its better delivery to the tumor [1]. Therefore, the LD
regimen is sufficient to achieve the most efficacy.
One limitation of this study was the tri-weekly treatment
schedule of nab-PTX q3w employed for patients with MBC. Previ-
ously, several studies have demonstrated that a weekly sb-PTX
might be more effective and less toxic than q3w administration
for early or MBC [11,12]. Seidman and colleagues also compared
weekly sb-PTX (80mg/m2) with q3w sb-PTX (175mg/m2) regimens
in patients with MBC and have shown that the weekly PTX was
superior to q3w administration: ORR, time-to-progression, and OS
[11]. Further, Sparano and colleagues enrolled 4950 patients with
early breast cancer and randomized sb-PTX either q3w or every
week following doxorubicin and cyclophosphamide, and found that
disease-free survival and OS were significantly improved [12].
Furthermore, weekly nab-PTX was superior to the q3w regimen, in
terms of efficacy and toxicity [13]. The weekly schedule of sb- or
nab-PTX is more commonly used to treat patients with breast
cancer, and the significance of our findings with the reduced dose
of q3w nab-PTX may be limited. Nab-PTX at 100 mg/m2 can be
administered weekly to reduce the incidence and degree of
myalgia. Nonetheless, it was not until recently that the weekly nab-
PTX regimen was adopted in Japan to treat patients with MBC due
to previous failures to demonstrate its superiority to q3w docetaxel
[14]. Moreover, there must be room for less frequent and toxic
regimens, especially for patients with limited access to clinics or
those who may benefit from minimizing the risk of coronavirus
infection during the COVID-19 pandemic.
The second limitation of the current study was that this was an
exploratory trial with small sample sizes in each treatment group,
and 28 patients included in the study withdrew their consent. This
can have a major impact on PFS and neurotoxicity data. Neuro-
toxicity is cumulative, and patients who withdrew their consent
would not contribute to disease events. Moreover, patients in the(n ¼ 45) LD180 (n ¼ 48)
% 95% CI n % 95% CI
24.4 (12.9, 39.5) 7 14.6 (6.1, 27.8)
17.8 (8, 32.1) 6 12.5 (4.7, 25.2)
6.7 (1.4, 18.3) 1 2.1 (0.1, 11.1)
0 (0, 7.9) 0 0 (0, 7.4)
2.2 (0.1, 11.8) 0 0 (0, 7.4)
4.4 (0.5, 15.1) 0 0 (0, 7.4)
J. Tsurutani, F. Hara, M. Kitada et al. The Breast 55 (2021) 63e68medium-dose arm had both the highest withdrawal rate and the
best PFS results. Therefore, the results of such analysis should be
interpreted with caution. Further studies are required to affirm
whether all patients should receive the reduced dose of nab-PTX
from the first cycle; however, a reduced-dose regimen is a treat-
ment option without compromising efficacy before the patients
experience severe toxicities, such as grade 3/4 neurotoxicity or
myalgia. The reduced initial dose is endorsed by the consistent
efficacy observed with favorable toxicity profiles in Japanese pa-
tients, although larger studies may be warranted to confirm these
findings [7,8].
Finally, we considered only the grade of neurotoxicity to
determine the optimal dose; however, the length and reversibility
of neurotoxicity are the two very important parameters that should
be considered to interpret the results.
5. Conclusion
Intravenous administration of low-dose nab-PTX at 180 mg/m2
q3w may improve tolerability without compromising PFS in pa-
tients with MBC, and further evaluation is warranted to confirm
these findings in a larger trial.
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